Progesterone receptor membrane component 1/ Sigma-2 receptor associates with MAP1LC3B and promotes autophagy

Autophagy

Volumn 9, Issue 10, 2013, Pages 1566-1578

  Mir, Shakeel U R ^a   Schwarze, Steven R ^a   Jin, Ling ^a   Zhang, Jinling ^a   Friend, Woodrow ^a   Miriyala, Sumitra ^a   Clair, Daret St ^a   Craven, Rolf J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Autophagy; Metabolism; Therapeutics; TOR; Ubiquitin

Indexed keywords

ADENYLATE KINASE; CYTOCHROME; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; MICROTUBULE PROTEIN; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PROTEIN MAP1LC3B; PROTEIN TSC1; ROTEIN UVRAG; S6 KINASE; STAT5A PROTEIN; STAT5B PROTEIN; TUBERIN; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAP1LC3B PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PROGESTERONE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; BIOACCUMULATION; CELL ORGANELLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; GENE; HUMAN; HUMAN CELL; METASTASIS; MITOCHONDRION; PGRMC1 GENE; PROTEIN CLEAVAGE; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TUMOR GROWTH; TUMOR INVASION; UBIQUITINATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROTEIN DEGRADATION; TUBEROUS SCLEROSIS; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEOLYSIS; RECEPTORS, PROGESTERONE; RECEPTORS, SIGMA; TUBEROUS SCLEROSIS;

EID: 84885646346     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.25889     Document Type: Article

References (73)

1. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev 2011; 25:1999-2010; PMID:21979913; http://dx.doi.org/10.1101/gad.17558811
2. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42; PMID:18191218; http://dx.doi.org/10.1016/j.cell.2007.12.018
3. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009; 34:259-69; PMID:19450525; http://dx.doi.org/10.1016/j. molcel.2009.04.026
4. Kirisako T, Ichimura Y, Okada H, Kabeya Y, Mizushima N, Yoshimori T, Ohsumi M, Takao T, Noda T, Ohsumi Y. The reversible modification regulates the membrane-binding state of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole targeting pathway. J Cell Biol 2000; 151:263-76; PMID:11038174; http://dx.doi.org/10.1083/jcb.151.2.263
5. Ichimura Y, Kirisako T, Takao T, Satomi Y, Shimonishi Y, Ishihara N, Mizushima N, Tanida I, Kominami E, Ohsumi M, et al. A ubiquitin-like system mediates protein lipidation. Nature 2000; 408:488-92; PMID:11100732; http://dx.doi.org/10.1038/35044114
6. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010; 466:68-76; PMID:20562859; http://dx.doi.org/10.1038/nature09204
7. Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex-at the crossroads of autophagy and beyond. Trends Cell Biol 2010; 20:355-62; PMID:20356743; http://dx.doi.org/10.1016/j.tcb.2010.03.002
8. Thoresen SB, Pedersen NM, Liestøl K, Stenmark H. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res 2010; 316:3368-78; PMID:20643123; http://dx.doi.org/10. 1016/j.yexcr.2010.07.008
9. Liang C, Lee JS, Inn KS, Gack MU, Li Q, Roberts EA, Vergne I, Deretic V, Feng P, Akazawa C, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol 2008; 10:776-87; PMID:18552835; http://dx.doi.org/10.1038/ncb1740
10. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011; 2:380; PMID:21730960; http://dx.doi.org/10.1038/ncomms1386
11. Mifsud W, Bateman A. Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol 2002; 3:H0068; PMID:12537557; http://dx.doi.org/10.1186/gb-2002-3-12-research0068
12. Min L, Strushkevich NV, Harnastai IN, Iwamoto H, Gilep AA, Takemori H, Usanov SA, Nonaka Y, Hori H, Vinson GP, et al. Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J 2005; 272:5832-43; PMID:16279947; http://dx.doi.org/10.1111/j.1742-4658.2005.04977.x
13. Rohe HJ, Ahmed IS, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 2009; 121:14-9; PMID:18992768; http://dx.doi.org/10.1016/j.pharmthera.2008.09.006
14. Falkenstein E, Meyer C, Eisen C, Scriba PC, Wehling M. Full-length cDNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells. Biochem Biophys Res Commun 1996; 229:86-9; PMID:8954087; http://dx.doi.org/10.1006/bbrc.1996.1761
15. Selmin O, Lucier GW, Clark GC, Tritscher AM, Vanden Heuvel JP, Gastel JA, Walker NJ, Sutter TR, Bell DA. Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzop-dioxin in rat liver. Carcinogenesis 1996; 17:2609-15; PMID:9006096; http://dx.doi.org/10.1093/carcin/17.12.2609
16. Gerdes D, Wehling M, Leube B, Falkenstein E. Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 1998; 379:907-11; PMID:9705155
17. Mir SU, Ahmed IS, Arnold S, Craven RJ. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 2012; 131:E1-9; PMID:21918976; http://dx.doi.org/10.1002/ijc.26432
18. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab 2008; 93:1592-9; PMID:18319313; http://dx.doi.org/10.1210/jc.2007-2771
19. Hou C, Tu Z, Mach R, Kung HF, Kung MP. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol 2006; 33:203-9; PMID:16546674; http://dx.doi.org/10.1016/j.nucmedbio.2005.10.001
20. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000; 82:1223-32; PMID:10735510; http://dx.doi.org/10.1054/bjoc.1999.1067
21. Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer 2010; 9:298; PMID:21092190; http://dx.doi.org/10.1186/1476-4598-9-298
22. Thompson AM, Reddi AR, Shi X, Goldbeck RA, Moenne-Loccoz P, Gibney BR, et al. Measurement of the Heme Affinity for Yeast Dap1p, and Its Importance in Cellular Function. Biochem 2007
23. Hughes AL, Powell DW, Bard M, Eckstein J, Barbuch R, Link AJ, Espenshade PJ. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007; 5:143-9; PMID:17276356; http://dx.doi.org/10.1016/j.cmet.2006.12.009
24. Crudden G, Chitti RE, Craven RJ. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J Pharmacol Exp Ther 2006; 316:448-55; PMID:16234411; http://dx.doi.org/10.1124/jpet.105.094631
25. Hand RA, Jia N, Bard M, Craven RJ. Saccharomyces cerevisiae Dap1p, a novel DNA damage response protein related to the mammalian membraneassociated progesterone receptor. Eukaryot Cell 2003; 2:306-17; PMID:12684380; http://dx.doi.org/10.1128/EC.2.2.306-317.2003
26. Mallory JC, Crudden G, Johnson BL, Mo C, Pierson CA, Bard M, Craven RJ. Dap1p, a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in Saccharomyces cerevisiae. Mol Cell Biol 2005; 25:1669-79; PMID:15713626; http://dx.doi.org/10.1128/MCB.25.5.1669-1679.2005
27. Craven RJ, Mallory JC, Hand RA. Regulation of iron homeostasis mediated by the heme-binding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51. J Biol Chem 2007; 282:36543-51; PMID:17954932; http://dx.doi.org/10.1074/jbc. M706770200
28. Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, Vogel U, Sotlar K, Wallwiener D, Kurek R, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10:R85; PMID:18922159; http://dx.doi.org/10.1186/bcr2155
29. Ahmed IS, Rohe HJ, Twist KE, Mattingly MN, Craven RJ. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J Pharmacol Exp Ther 2010; 333:564-73; PMID:20164297; http://dx.doi.org/10.1124/jpet.109.164210
30. Hand RA, Craven RJ. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem 2003; 90:534-47; PMID:14523988; http://dx.doi.org/10.1002/jcb.10648
31. Ahmed IS, Rohe HJ, Twist KE, Craven RJ. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010; 285:24775-82; PMID:20538600; http://dx.doi.org/10.1074/jbc.M110.134585
32. Peluso JJ, Liu X, Gawkowska A, Lodde V, Wu CA. Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. Mol Cell Endocrinol 2010; 320:153-61; PMID:20144686; http://dx.doi.org/10.1016/j.mce.2010.02.005
33. Peluso JJ, Pappalardo A, Losel R, Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 2006; 147:3133-40; PMID:16513825; http://dx.doi.org/10.1210/en.2006-0114
34. Peluso JJ, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008; 149:534-43; PMID:17991724; http://dx.doi.org/10.1210/en. 2007-1050
35. Kashiwagi H, McDunn JE, Simon PO Jr., Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med 2009; 7:24; PMID:19323815; http://dx.doi.org/10. 1186/1479-5876-7-24
36. Ostenfeld MS, Fehrenbacher N, Høyer-Hansen M, Thomsen C, Farkas T, Jäättelä M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005; 65:8975-83; PMID:16204071; http://dx.doi.org/10.1158/0008-5472.CAN-05-0269
37. Ostenfeld MS, Høyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, Puustinen P, Kirkegaard-Sørensen T, Nylandsted J, Farkas T, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 2008; 4:487-99; PMID:18305408
38. Groth-Pedersen L, Ostenfeld MS, Høyer-Hansen M, Nylandsted J, Jäättelä M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 2007; 67:2217-25; PMID:17332352; http://dx.doi.org/10.1158/0008-5472.CAN-06-3520
39. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 1995; 278:151-60; PMID:7671999; http://dx.doi.org/10.1016/0014- 2999(95)00115-2
40. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62:313-22; PMID:11782394
41. Spitzer D, Simon PO Jr., Kashiwagi H, Xu J, Zeng C, Vangveravong S, Zhou D, Chang K, McDunn JE, Hornick JR, et al. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res 2012; 72:201-9; PMID:22065721; http://dx.doi.org/10.1158/0008-5472. CAN-11-1354
42. Yoshitani N, Satou K, Saito K, Suzuki S, Hatanaka H, Seki M, Shinozaki K, Hirota H, Yokoyama S. A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements. Proteomics 2005; 5:1472-80; PMID:15798990; http://dx.doi.org/10.1002/pmic.200401032
43. Park J, Chung S, An H, Kim J, Seo J, Kim DH, Yoon SY. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience 2012; 209:64-73; PMID:22390943; http://dx.doi.org/10.1016/j. neuroscience.2012.02.035
44. Mo RH, Zaro JL, Ou JH, Shen WC. Effects of Lipofectamine 2000/siRNA complexes on autophagy in hepatoma cells. Mol Biotechnol 2012; 51:1-8; PMID:21660602; http://dx.doi.org/10.1007/s12033-011-9422-6
45. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253:905-9; PMID:1715094; http://dx.doi.org/10.1126/science.1715094
46. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78:35-43; PMID:7518356; http://dx.doi.org/10.1016/0092-8674(94)90570-3
47. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-8; PMID:8008069; http://dx.doi.org/10.1038/369756a0
48. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; http://dx.doi.org/10.1038/nrm3025
49. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 2011; 30:2289-303; PMID:21258412; http://dx.doi.org/10.1038/onc.2010.630
50. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13:1259-68; PMID:12906785; http://dx.doi.org/10.1016/S0960-9822(03)00506-2
51. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002; 99:13571-6; PMID:12271141; http://dx.doi.org/10.1073/pnas. 202476899
52. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577-90; PMID:14651849; http://dx.doi.org/10.1016/S0092-8674(03)00929-2
53. Mann SS, Hammarback JA. Molecular characterization of light chain 3. A microtubule binding subunit of MAP1A and MAP1B. J Biol Chem 1994; 269:11492-7; PMID:7908909
54. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.1074/jbc. M702824200
55. Tsukada M, Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett 1993; 333:169-74; PMID:8224160; http://dx.doi.org/10.1016/0014-5793(93)80398-E
56. Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 1998; 273:3963-6; PMID:9461583; http://dx.doi.org/10.1074/jbc.273.7.3963
57. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284:8023-32; PMID:19150980; http://dx.doi.org/10.1074/jbc. M900301200
58. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol 2000; 150:1507-13; PMID:10995454; http://dx.doi.org/10.1083/jcb.150.6.1507
59. Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012; 32:2-11; PMID:22025673; http://dx.doi.org/10.1128/MCB.06159-11
60. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8:774-85; PMID:17712357; http://dx.doi.org/10.1038/nrm2249
61. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13:1016-23; PMID:21892142; http://dx.doi.org/10.1038/ncb2329
62. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17:1829-34; PMID:12869586; http://dx.doi.org/10.1101/gad.1110003
63. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11:1457-66; PMID:12820960; http://dx.doi.org/10.1016/S1097-2765(03)00220-X
64. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5:578-81; PMID:12771962; http://dx.doi.org/10.1038/ncb999
65. Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, Wang Y, Xia LP, Feng GK, Liu QQ, et al. The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene 2009; 28:886-98; PMID:19060920; http://dx.doi.org/10.1038/onc.2008.441
66. Lorin S, Borges A, Ribeiro Dos Santos L, Souquère S, Pierron G, Ryan KM, Codogno P, Djavaheri-Mergny M. c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated Ewing sarcoma cells. Cancer Res 2009; 69:6924-31; PMID:19706754; http://dx.doi.org/10.1158/0008-5472.CAN-09-1270
67. Mir SU, Jin L, Craven RJ. Neutrophil gelatinaseassociated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem 2012; 287:14494-501; PMID:22418433; http://dx.doi.org/10. 1074/jbc.M111.324921
68. Sambade M, Alba M, Smardon AM, West RW, Kane PM. A genomic screen for yeast vacuolar membrane ATPase mutants. Genetics 2005; 170:1539-51; PMID:15937126; http://dx.doi.org/10.1534/genetics.105.042812
69. Vadlamudi RK, Joung I, Strominger JL, Shin J. p62, a phosphotyrosine- independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitinbinding proteins. J Biol Chem 1996; 271:20235-7; PMID:8702753; http://dx.doi.org/10.1074/jbc.271.34.20235
70. Hornick JR, Vangveravong S, Spitzer D, Abate C, Berardi F, Goedegebuure P, Mach RH, Hawkins WG. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J Exp Clin Cancer Res 2012; 31:41; PMID:22551149; http://dx.doi.org/10.1186/1756-9966-31-41
71. Wei Z, Mousseau DD, Dai Y, Cao X, Li XM. Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS. Pharmacogenomics J 2006; 6:279-88; PMID:16462815
72. Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 2000; 74:211-8; PMID:10812960; http://dx.doi.org/10.1016/S0031- 6865(99)00034-5
73. Monassier L, Manoury B, Bellocq C, Weissenburger J, Greney H, Zimmermann D, Ehrhardt JD, Jaillon P, Baró I, Bousquet P. sigma(2)-receptor ligandmediated inhibition of inwardly rectifying K(+) channels in the heart. J Pharmacol Exp Ther 2007; 322:341-50; PMID:17460149; http://dx.doi.org/10.1124/ jpet.107.122044